Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer.
Forty patients with metastatic breast cancer were treated with a combination of continuous 5-day infusion vinblastine and peptichemio. All patients had received prior therapy with 5-fluorouracil, adriamycin, cyclophosphamide and methotrexate. Vinblastine was given at a dose of 1.2 mg/m2/day for 5 days. Following completion of the 5-day infusion vinblastine, peptichemio was given as a rapid I.V. injection at a dose of 60 mg/m2. Ten partial responses (30%) were observed among the 33 evaluable patients with a median time to treatment failure of 6 months. Myelosuppression, predominantly granulocytopenia, was the major toxicity resulting from this combination. The response rate of this combination is not better than that observed with continuous 5-day infusion vinblastine alone.
D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced; D001943:Breast Neoplasms / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008558:Melphalan / Q000031:analogs & derivatives*; D008875:Middle Aged; D010440:Peptichemio / Q000008:administration & dosage* / Q000009:adverse effects; D014747:Vinblastine / Q000008:administration & dosage* / Q000009:adverse effects
D014747:Vinblastine; D010440:Peptichemio; D008558:Melphalan